Bright Minds Biosciences Inc (DRUG) — Strategic Asset Allocation Index
Bright Minds Biosciences Inc (DRUG) has a Strategic Asset Allocation Index of 1.1% as of December 2022. Strategic assets (PP&E of $120.75K plus long-term investments of $-) total $120.75K, measured against net assets of $10.97 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Bright Minds Biosciences Inc Strategic Asset Allocation Index (2022–2022)
This chart shows how Bright Minds Biosciences Inc's Strategic Asset Allocation Index has evolved across 1 annual periods from 2022 to 2022. As of December 2022, the index stands at 1.1%, representing strategic assets of $120.75K against net assets of $10.97 Million USD. Explore DRUG cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Bright Minds Biosciences Inc (2022–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Bright Minds Biosciences Inc from 2022 to 2022, covering 1 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market value of Bright Minds Biosciences Inc.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 1.3% | $138.86K | $138.86K | $- | $10.54 Million | — |